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Aureĺie Mallinger,*,† Kai Schiemann,‡ Christian Rink,† Jimmy Sejberg,† Mark A. Honey,†
Paul Czodrowski,‡ Mark Stubbs,† Oliver Poeschke,‡ Michael Busch,‡ Richard Schneider,‡
Daniel Schwarz,‡ Djordje Musil,‡ Rosemary Burke,† Klaus Urbahns,‡ Paul Workman,† Dirk Wienke,‡
Paul A. Clarke,† Florence I. Raynaud,† Suzanne A. Eccles,† Christina Esdar,‡ Felix Rohdich,‡
and Julian Blagg*,†
†Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK
‡Merck KGaA, Darmstadt 64293, Germany
*S Supporting Information
ABSTRACT: We demonstrate a designed scaﬀold-hop
approach to the discovery of 2,8-disubstituted-1,6-naphthyr-
idine- and 4,6-disubstituted-isoquinoline-based dual CDK8/19
ligands. Optimized compounds in both series exhibited rapid
aldehyde oxidase-mediated metabolism, which could be
abrogated by introduction of an amino substituent at C5 of
the 1,6-naphthyridine scaﬀold or at C1 of the isoquinoline
scaﬀold. Compounds 51 and 59 were progressed to in vivo
pharmacokinetic studies, and 51 also demonstrated sustained
inhibition of STAT1SER727 phosphorylation, a biomarker of
CDK8 inhibition, in an SW620 colorectal carcinoma human tumor xenograft model following oral dosing.
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Mediator complex-associated kinases CDK8 and CDK19are involved in the regulation of multiple transcription
pathways; notably, CDK8 has been implicated as an oncogene
in colorectal and gastric cancers through activation of WNT
signaling.1−4 There has been increasing interest in small
molecule modulators of CDK8 including Sorafenib,5 Senexin
A,6 Cortistatin A,7 and a recently reported series of 6-aza-
benzothiophenes.8 In addition, we have reported the discovery
and optimization of a 3,4,5-trisubstituted pyridine series to give
CCT251545 (1) and CCT251921 (2), potent, selective, and
orally bioavailable dual CDK8/19 ligands (Figure 1).9−11 In the
course of this work, we were keen to expand the range of
CDK8/19 inhibitors and sought a structurally diﬀerentiated
backup series. Our eﬀorts focused upon replacement of the
pyridine core, cognizant of our previously reported observation
that both in vitro CDK8/19 aﬃnity and potent cell-based
activity of this series beneﬁted from a twisted conformation
about the planes of the piperidine and pyridine rings; such a
twisted conformation is also observed in CDK8-ligand cocrystal
structures enabling the lactam amide to bridge Lys52 and
Asp173 in CDK8 (Figure 1).10,11 We hypothesized that
construction of a 6-membered ring across the 3- and 4-
positions of the pyridine, while breaking the piperidine ring,
would provide a scaﬀold hop with suﬃcient ﬂexibility to
maintain key lactam amide interactions with CDK8 (Figure 1).
This rigidiﬁcation−derigidiﬁcation tactic generated target 3 that
we simpliﬁed by retrosynthetic analysis and considerations of
synthetic tractability to a 2,8-disubstitued-1,6-naphthyridine
scaﬀold exempliﬁed by 4. We were concerned that the aromatic
1,6-naphthyridine scaﬀold precludes the twisted conformation
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Figure 1. 3,4,5-Trisubstituted pyridine series and scaﬀold-hop to the
1,6-naphthyridine series.
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observed in ligand-bound structures of the 3,4,5-trisubstituted
pyridine series; furthermore, preparation of amides such as 4,
while synthetically feasible, may not adequately mimic the
precedented interaction of spiroamides 1 and 2 with Lys52.
With these caveats in mind, we set out to explore the 1,6-
naphthyridine scaﬀold by incorporating substituents at the C-8
position that had proved optimal at C-5 in the 3,4,5-
trisubstituted pyridine series.11 Pleasingly, the hypothesized
combination of a methylpyrazolylphenyl substituent at C-8 and
methyl amide at C-2 of the 1,6-naphthyridine scaﬀold
(compound 4, Table 1) led to potent CDK8 aﬃnity that
translated to inhibition of WNT signaling in our previously
described luciferase reporter assay in HEK293 7dF3 cells.11
Similarly, compound 5 and isomer 6 bearing a methylindazole
at the C-8 position were also potent; however, compounds 4−6
were all metabolically unstable (Table 1). Gratifyingly,
introduction of an N-methyl or NH sultam (7 and 8, Table
1) improved metabolic stability while maintaining potency.
To compare the binding mode of the 1,6-naphthyridine
series with the 3,4,5-trisubstituted pyridine series, we solved the
crystal structure of 7 in complex with the kinase domain of
CDK8 and cyclin C (Pdb code: 5I5Z). Consistent with our
hypothesis, 7 binds in the ATP binding site with the
naphthyridine N-6 nitrogen interacting with the backbone
NH of the hinge residue Ala100 (Figure 2A). Notably, the C2-
amide carbonyl interacts with Lys52, and the C-8 phenyl
substituent forms a pi−cation interaction with Arg356
consistent with our previous observations in the 3,4,5-
trisubsitiuted pyridine series.10,11 Overlay of 7 with 1
(CCT251545) conﬁrmed our design strategy; most notably,
both the methylamide of 7 and spirolactam of 1 interact with
Lys52. Additionally, C-3 and C-4 of the naphthyridine ring are
3.7 and 3.9 Å from the closest gatekeeper heavy atom indicating
that the hydrophobic interactions of the C3−Cl in 1 are
maintained in 7 (Figure 2B).
We next explored optimization of the N-methylamide at C-2.
The primary amide 9 (Table 2) proved equally potent and
stable as methylamide 4 (Table 1). Compared to methylamide
4, a drop in cell-based potency was seen with the carboxylic
acid 10 (Table 2), while introduction of a nitrile led to a drop
in potency in both the biochemical- and cell-based assays
(Table 2).
Azetidine amide 12 proved potent but metabolically
unstable, and introduction of methoxy or geminal diﬂuoro
substitution at C-3 of the azetidine (13 and 14) did not
signiﬁcantly reduce in vitro clearance. Consistent with azetidine
amide 12, pyrrolidine amide 15 was potent but exhibited poor
metabolic stability. The more sterically demanding 6-membered
morpholino and piperazine amides 16 and 17 were less potent,
and no improvement in in vitro clearance was observed.
Reverse amide 18 and lactone 19 maintained biochemical
potency relative to 4; however, both compounds proved 10-
fold less active in the cell-based assay. Imidazolidinone 20,
bearing a better hydrogen bond acceptor than lactone 19,
demonstrated improved potency compared with 18 and 19 but
suﬀered from suboptimal metabolic stability. Removal of the
carbonyl group (21 and 22) led to a > 250-fold drop in CDK8
aﬃnity consistent with the loss of a beneﬁcial interaction with
Lys52.
We next turned our attention to the introduction of
heterocycles as amide isosteres at C-2 of the 1,6-naphthyridine
scaﬀold. Pyrazoles 23 and 24 gave a signiﬁcant drop in potency,
whereas isoxazole 25 and N-methylimidazole 26 restored
CDK8 aﬃnity and cell-based inhibition of WNT signaling. We
hypothesize that N-methylimidazole at C-2 may optimally
bridge Lys52 and Asp173; however, 26 proved to be
metabolicallly unstable and was not pursued further.
The X-ray crystal structure of 7 in CDK8 indicates that the
N-1 nitrogen of the 1,6-napthyridine scaﬀold does not interact
directly with the protein, and we therefore investigated the
corresponding isoquinoline analogues. Compound 27 (Table
3), the matched pair of 4 (Table 1), conﬁrmed that
isoquinolines may have potential. Similarly, the secondary and
tertiary amides (28−30, Table 3), reverse amide 31, oxazole 32,
and N-methylimidazole 33 all demonstrated potent aﬃnity for
CDK8 but also proved metabolically unstable. Unsurprisingly,
we observed similar SAR trends between the 1,6-naphthyridine
and isoquinoline series. Additional functionality was tested at
the C-6 position; the cyclic carbamate 34 had potent CDK8
aﬃnity and cell-based activity but suﬀered from a suboptimal
Clint proﬁle, whereas sulphonamides 35 and 36 proved less
active in the cell-based assay (7- and 12-fold drop oﬀ,
respectively) without improvement in metabolic stability.
At this stage, compounds 7, 8, and 17, which exhibited the
best in vitro mouse microsomal stability, were progressed to in
Table 1. Introduction of Optimal Substituents at C-8 of the
1,6-Naphthyridine Scaﬀold12
aM, mouse; R, rat; H, human.
Figure 2. (A) X-ray crystal structure of 7 in CDK8/Cyclin C. (B)
Overlay of 7 (cyan) with CCT251545 (pink).
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vivo PK studies in Balb/C mice (Table S1). Unfortunately, all
compounds revealed a clearance that exceeded liver blood ﬂow.
Although compound 8 is an eﬄux substrate (Table S1), this
ﬁnding could not explain the observed high in vivo clearance
across all three compounds.
Cognizant of the propensity for bicyclic heterocyclic
aromatic systems to be aldehyde oxidase (AO) substrates,13
we examined metabolic turnover for exemplar 1,6-naphthyr-
idines and isoquinolines in an AO assay. Disappointingly, we
observed rapid turnover for all compounds examined (Table
S2). Met-ID studies of 8 in human hepatocytes, followed by
isolation and NMR analysis, suggested oxidation to give the C5-
OH compound 37 as the main metabolite, which we
subsequently conﬁrmed by independent synthesis (Figure
S1). Unfortunately, 37 proved inactive versus CDK8 indicating
that a C5-hydroxyl group is not tolerated.
We, therefore, turned our attention to the design of
compounds that have the potential to block the AO metabolism
and maintain aﬃnity for CDK8 and CDK19. First, we checked
if pendant polar groups on the terminal pyrazole would reduce
the rate of AO-mediated metabolism. In this context, several
compounds in the 1,6-naphthyridine and isoquinoline series
were prepared (Table S3); however, in all cases, pendant polar
functionality failed to reduce AO metabolism. On the basis of
these results, we next attempted the introduction of alternative
substituents at C5 of the napthyridine scaﬀold, which had the
potential to block AO metabolism while also being compatible
with the known binding mode to the hinge region of CDK8
(Figure 2). Introduction of a methoxy, methyl, or diﬂuoro-
methyl group into the optimized exemplars of the 1,6-
naphthyridine and 2-isoquinoline series led to a signiﬁcant
drop in CDK8 aﬃnity (Table S4). However, introduction of an
amino group maintained potency consistent with our
previously exempliﬁed progression from a 3,4,5-trisubstituted
pyridine series to a 3,4,5-trisubstituted 2-aminopyridine
series;11 gratifyingly, this tactic successfully blocked AO-
Table 2. Amide Variation at C-2 of the 1,5-Naphthyridine
Series12
Table 3. Isoquinoline Analogues12
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mediated metabolism for compounds 48 and 49 (Table S4).
Compounds 48 and 49 (Table 4), direct amino analogues of 7
(Table 1) and 17 (Table 2), demonstrated acceptable in vitro
metabolic stability, and in vivo PK properties were determined
in Balb/C mice. In the case of 49, lower in vivo clearance
compared with 17 was observed (Table 4); however, low oral
bioavailability consistent with low passive permeability was also
noted (Table 5).
On the basis of in vitro AO metabolism data and in vivo PK
of 49, we sought additional C-5 amino derivatives. Pleasingly,
replacement of piperazine by morpholine 50 or methoxyaze-
tidine 51 to reduce the HBD count increased permeability and
reduced eﬄux ratio (Table 5). We attempted to further reduce
Caco-2 eﬄux liability by removing or masking HBAs (52 and
53); however, no improvement was observed. Installation of
3,3-diﬂuoro or 3-ﬂuoro-3-methylazetidine, 54 and 55, respec-
tively, led to an acceptable eﬄux ratio; however, further
proﬁling revealed mouse plasma instability, possibly due to
amidase-mediated amide hydrolysis. Pyrrolidine amide 56 was
prepared as an alternative to the unstable ﬂuoroazetidines;
disappointingly, no improvement in eﬄux ratio was observed,
and aﬃnity for CDK8 was eroded. We also prepared 57, the
C5-amino analogue of 26 (Table 2), which resulted in a
surprising and unexplained loss of CDK8 aﬃnity (225-fold).
To further explore the potential for blocking AO-
metabolism, we prepared 1-aminoisoquinolines including
selected matched pairs of the corresponding 1,6-naphthyridine
series (Table 5). Removal of one HBA from the 1,6-
naphthyridine to the isoquinoline scaﬀold did not result in a
lower eﬄux ratio, presumably due to the buried location of the
N-1 nitrogen atom, which renders its removal insigniﬁcant in
terms of overall polarity and solvation potential (compounds
58−60). Consistent with the naphthyridine series, the 3,3-
diﬂuoro or 3-ﬂuoro-3-methylazetidine amides, while providing
lower eﬄux ratios, exhibited plasma instability (compounds 61
and 62). Additional exemplar amino-isoquinoline derivatives
demonstrated improved metabolic stability versus their
corresponding isoquinoline matched pairs; however, eﬄux
ratios were suboptimal (63−65).
Selected C5-aminonaphthyridine and C1-amino-isoquinoline
derivatives were tested in the AO-substrate assay and also in the
chemical Litmus Test recently reported as a practical and
convenient surrogate assay for AO-mediated metabolism.14
Consistent with expectation, all amino derivatives tested were
stable in both the AO-substrate assay and Litmus Test, while all
unsubstituted derivatives were unstable in both assays (Table
S5). Thus, the Litmus Test proved a useful and accurate
predictor for AO-mediated metabolism in this chemical series.
As a result of their favorable in vitro proﬁles, we selected 51
and 59 for further characterization and in vivo evaluation. Both
compounds bind to CDK8 and CDK19 in the presence of
cyclin C with similar aﬃnity (5 nM and 6 nM, respectively, for
51; 33 nM and 19 nM, respectively, for 59; Table 6). We have
previously reported that modulation of phospho-STAT1SER727
is a useful cell-based and in vivo biomarker for CDK8
inhibition.10 Both 51 and 59 demonstrated potent inhibition
of phospho-STAT1SER727 in SW620 human colorectal carcino-
ma cells harboring an activating APC-mutation, indicating good
Table 4. Pharmacokinetics of Compounds 7, 17, 48, and
4912
Table 5. Amino Derivatives12
aindicates PappA‑B: × 10
−6 cm/s.
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translation to cell-based activity; both compounds were tested
against a panel of >250 kinases and inhibited only a single
kinase by more than 50% at 1 μM (FLT4: 54% and 62%
inhibition, respectively) (Table S6). On the basis of these
encouraging ﬁndings, naphthyridine 51 and isoquinoline 59
were studied in in vivo mouse and rat PK experiments. Both
compounds demonstrated medium in vivo clearance and Vd
but low bioavailability in mice, likely due to their aﬃnity for
eﬄux transporters. Indeed, we observed 20−40% of the parent
compound excreted unchanged in feces after iv dosing
indicative of hepatic uptake and biliary excretion.11
Compound 51 was progressed to a PK/PD study in a SW620
colorectal carcinoma human tumor xenograft model. After a
single 5 mg/kg po dose, we observed time-dependent
inhibition of phospho-STAT1SER727 (Figure 3) consistent with
plasma exposure (Figure S2) suggesting that a b.i.d. schedule
would be required at this dose to maintain maximal target
engagement.
In conclusion, starting from the 3,4,5-trisubstituted pyridine
CCT251545, we designed a scaﬀold-hop that led to the
discovery of 2,8-disubstituted-1,6-naphthyridine- and 4,6-
disubstituted-isoquinolines-based dual CDK8/19 ligands.
Protein−ligand crystal structure determination in CDK8
conﬁrmed a Type I binding mode and key interactions with
Ala100 (hinge), Phe97 (gatekeeper), Lys52 (catalytic residue),
as well as Arg356 from the CDK8 C-terminus. Both the
naphthyridine and isoquinoline scaﬀolds exhibited site-speciﬁc
AO-mediated metabolism, which could be blocked by the
introduction of amino groups at C5 and C1, respectively.
Notably, susceptibility to AO metabolism in both chemical
series was entirely consistent with the chemical Litmus Test.14
Minimisation of eﬄux led to the synthesis of 51 and 59, both of
which demonstrated acceptable oral pharmacokinetics; 51 also
demonstrated inhibition of phospho-STAT1SER727, a biomarker
of CDK8 inhibition, on oral dosing in an SW620 human
colorectal carcinoma xenograft model. Compound 51 is an
advanced chemical tool with which to further explore the
eﬃcacy, safety, and tolerability of dual CDK8/19 ligands.
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(5) Schneider, E. V.; Böttcher, J.; Blaesse, M.; Neumann, L.; Huber,
R.; Maskos, K. The Structure of CDK8/CycC Implicates Specificity in
the CDK/Cyclin Family and Reveals Interaction with a Deep Pocket
Binder. J. Mol. Biol. 2011, 412, 251−266.
(6) Porter, D. C.; Farmaki, E.; Altilia, S.; Schools, G. P.; West, D. K.;
Chen, M.; Chang, B. D.; Puzyrev, A. T.; Lim, C.; Rokow-Kittell, R.;
et al. Cyclin-Dependent Kinase 8 Mediates Chemotherapy Induced
Tumor-Promoting Paracrine Activities. Proc. Natl. Acad. Sci. U. S. A.
2012, 109, 13799−13804.
(7) Pelish, H. E.; Liau, B. B.; Nitulescu, I. I.; Tangpeerachaikul, A.;
Poss, Z. C.; Da Silva, D. H.; Caruso, B. T.; Arefolov, A.; Fadeyi, O.;
Christie, A. L.; Du, K.; Banka, D.; Schneider, E. V.; Jestel, A.; Zou, G.;
Si, C.; Ebmeier, C. C.; Bronson, R. T.; Krivtsov, A. V.; Myers, A. G.;
Kohl, N. E.; Kung, A. L.; Armstrong, S. A.; Lemieux, M. E.; Taatjes, D.
J.; Shair, M. D. Mediator kinase inhibition further activates
superenhancer-associated genes in AML. Nature 2015, 526, 273−276.
(8) Koehler, M. F. T.; Bergeron, P.; Blackwood, E. M.; Bowman, K.;
Clark, K. R.; Firestein, R.; Kiefer, J. R.; Maskos, K.; McCleland, M. L.;
Orren, L.; Salphati, L.; Schmidt, S.; Schneider, E. V.; Wu, J.; Beresini,
M. H. Development of a Potent, Specific CDK8 Kinase Inhibitor
Which Phenocopies CDK8/19 Knockout Cells. ACS Med. Chem. Lett.
2016, 7, 223.
(9) Mallinger, A.; Crumpler, S.; Pichowicz, M.; Waalboer, D.; Stubbs,
M.; Adeniji-Popoola, O.; Wood, B.; Smith, E.; Thai, C.; Henley, A. T.;
Georgi, K.; Court, W.; Hobbs, S.; Box, G.; Ortiz-Ruiz, M. J.; Valenti,
M.; De Haven Brandon, A.; TePoele, R.; Leuthner, B.; Workman, P.;
Aherne, W.; Poeschke, O.; Dale, T.; Wienke, D.; Esdar, C.; Rohdich,
F.; Raynaud, F.; Clarke, P. A.; Eccles, S. A.; Stieber, F.; Schiemann, K.;
Blagg, J. Discovery of Potent, Orally Bioavailable, Small-Molecule
Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. J.
Med. Chem. 2015, 58, 1717−1735.
(10) Dale, T.; Clarke, P. A.; Esdar, C.; Waalboer, D.; Adeniji-
Popoola, O.; Ortiz-Ruiz, M.; Mallinger, A.; Samant, R. S.; Czodrowski,
P.; Musil, D.; Schwarz, D.; Schneider, K.; Stubbs, M.; Ewan, K.; Fraser,
E.; TePoele, R.; Court, W.; Box, G.; Valenti, M.; de Haven Brandon,
A.; Gowan, S.; Rohdich, F.; Raynaud, F.; Schneider, R.; Poeschke, O.;
Blaukat, A.; Workman, P.; Schiemann, K.; Eccles, S. A.; Wienke, D.;
Blagg, J. Identification of a potent and selective chemical probe for
exploring the role of Mediator complex-associated protein kinases
CDK8 and CDK19 in human disease. Nat. Chem. Biol. 2015, 11, 973−
980.
(11) Mallinger, A.; Schiemann, K.; Rink, C.; Stieber, F.; Calderini,
M.; Crumpler, S.; Stubbs, M.; Adeniji-Popoola, O.; Poeschke, O.;
Busch, M.; Czodrowski, P.; Musil, D.; Schwarz, D.; Ortiz-Ruiz, M.-J.;
Schneider, R.; Thai, C.; Valenti, M.; De Haven Brandon, A.; Burke, R.;
Workman, P.; Dale, T.; Wienke, D.; Clarke, P. A.; Esdar, C.; Raynaud,
F. I.; Eccles, S. A.; Rohdich, F.; Blagg, J. J. Med. Chem. 2016, 59, 1078−
1101.
(12) Protocols for the 7dF3 cell-based assay, CDK8 binding aﬃnity,
microsomal stability (Clint), Caco2, mouse and rat PK can be found in
ref 11. IC50 data are reported as averages of at least two
determinations with standard deviations.
(13) Pryde, D. C.; Dalvie, D.; Hu, Q.; Jones, P.; Obach, R. S.; Tran,
T. D. Aldehyde oxidase: an enzyme of emerging importance in drug
discovery. J. Med. Chem. 2010, 53, 8441−60.
(14) O’Hara, F.; Burns, A. C.; Collins, M. R.; Dalvie, D.; Ornelas, M.
A.; Vaz, A. D. N.; Fujiwara, Y.; Baran, P. S. A Simple Litmus Test for
Aldehyde Oxidase Metabolism of Heteroarenes. J. Med. Chem. 2014,
57, 1616−1620.
ACS Medicinal Chemistry Letters Letter
DOI: 10.1021/acsmedchemlett.6b00022
ACS Med. Chem. Lett. 2016, 7, 573−578
578
